Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0SCDR)

Drug Name
Piretanide Drug Info
Synonyms
piretanide; 55837-27-9; Tauliz; Arlix; 4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid; Piretanido [Spanish]; HOE 118; Piretanidum [INN-Latin]; Piretanido [INN-Spanish]; UNII-DQ6KK6GV93; Arelix (TN); C17H18N2O5S; EINECS 259-852-9; Hoe-118; BRN 5633965; DQ6KK6GV93; 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic acid; 4-Phenoxy-3-(1-pyrrolidinyl)-5-sulfamoylbenzoic acid; S 734118; S 73 4118; NCGC00016878-01; 3-(Aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)-benzoic acid; Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidin
Cross-matching ID
PubChem CID
4849
ChEBI ID
CHEMBL349803
CAS Number
CAS 55837-27-9
TTD Drug ID
D09NNS

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 2.04 1.69e-2 48/60 (80%) MT1F;MT1M;MT1X;...
Proximal tubule bicarbonate reclamation 2.02 8.43e-3 21/23 (91.3%) PCK1;SLC4A4;CA2;...
Drug metabolism 1.98 5.62e-3 78/151 (51.66%) DUT;GSTO1;UGT2B28;...
Ascorbate and aldarate metabolism 1.95 8.43e-3 15/30 (50%) UGT2B28;UGT2B17;UGT2B15;...
PPAR signaling pathway 1.84 2.02e-2 66/74 (89.19%) PCK1;MMP1;FABP1;...
Mismatch repair 1.82 2.25e-2 22/23 (95.65%) PCNA;RPA3;MSH2;...
Pentose and glucuronate interconversions 1.81 2.29e-2 17/34 (50%) UGT2B28;UGT2B17;UGT2B15;...
Bile secretion 1.81 2.00e-2 68/90 (75.56%) SLC4A4;PRKACB;CA2;...
DNA replication 1.80 1.78e-2 34/36 (94.44%) PCNA;RPA3;POLE2;...
Endocrine and other factor-regulated calcium reabsorpti... 1.80 1.69e-2 49/53 (92.45%) PRKACB;ATP1A1;GNAQ;...
Cell cycle 1.80 1.61e-2 110/124 (88.71%) PCNA;CCNB2;ORC1;...
Glycolysis / Gluconeogenesis 1.77 1.76e-2 56/67 (83.58%) PCK1;ALDOB;ENO1;...
Metabolism of xenobiotics by cytochrome P450 1.77 1.62e-2 49/77 (63.64%) CYP1B1;GSTO1;UGT2B28;...
Carbohydrate digestion and absorption 1.77 1.57e-2 37/47 (78.72%) ATP1A1;SLC2A5;PLCB1;...
Fanconi anemia pathway 1.73 2.30e-2 36/54 (66.67%) RPA3;ATR;RMI1;...
Fatty acid degradation 1.73 2.27e-2 40/43 (93.02%) CPT1A;ADH1B;EHHADH;...
Homologous recombination 1.71 2.38e-2 35/41 (85.37%) RPA3;TOPBP1;RAD54B;...
Cysteine and methionine metabolism 1.70 2.39e-2 43/50 (86%) CDO1;BCAT1;MAT2A;...
Primary bile acid biosynthesis 1.69 2.26e-2 15/17 (88.24%) SLC27A5;AKR1C4;BAAT;...
Steroid hormone biosynthesis 1.66 2.87e-2 43/61 (70.49%) CYP1B1;UGT2B28;HSD11B1;...
Pyrimidine metabolism 1.65 3.01e-2 40/56 (71.43%) DUT;DCK;ENPP1;...
Pyruvate metabolism 1.62 4.79e-2 41/47 (87.23%) PCK1;ADH1B;ACAT2;...
Propanoate metabolism 1.61 4.76e-2 30/34 (88.24%) EHHADH;ALDH6A1;ECHS1;...
Starch and sucrose metabolism 1.61 4.78e-2 25/36 (69.44%) GBE1;ENPP1;MGAM;...
Dilated cardiomyopathy -1.62 4.38e-2 86/96 (89.58%) SGCA;CACNG4;SLC8A2;...
B cell receptor signaling pathway -1.63 4.27e-2 71/81 (87.65%) LILRA4;AKT1;FOS;...
Hematopoietic cell lineage -1.64 4.35e-2 90/99 (90.91%) IL4R;CD22;HLA-DRB1;...
Apoptosis -1.65 4.11e-2 126/168 (75%) GADD45G;AKT1;MAPK8;...
Graft-versus-host disease -1.68 3.63e-2 32/42 (76.19%) IFNG;GZMB;TNF;...
Primary immunodeficiency -1.73 2.38e-2 33/38 (86.84%) TAP1;RFX5;BTK;...
Renal cell carcinoma -1.73 2.44e-2 68/69 (98.55%) TFE3;AKT1;GAB1;...
ErbB signaling pathway -1.73 2.58e-2 79/85 (92.94%) AKT1;GAB1;STAT5A;...
Tuberculosis -1.73 2.66e-2 159/180 (88.33%) HLA-DOB;AKT1;NFYC;...
Osteoclast differentiation -1.76 2.23e-2 117/127 (92.13%) TYK2;MAPK8;IFNB1;...
Autoimmune thyroid disease -1.76 2.14e-2 46/53 (86.79%) GZMB;PRF1;HLA-DOA;...
Hypertrophic cardiomyopathy -1.77 2.04e-2 81/90 (90%) SGCA;CACNG4;SLC8A2;...
Steroid biosynthesis -1.79 1.92e-2 19/20 (95%) CYP24A1;TM7SF2;HSD17B7;...
Th17 cell differentiation -1.79 2.08e-2 95/107 (88.79%) HLA-DOB;STAT5A;TYK2;...
Th1 and Th2 cell differentiation -1.82 1.84e-2 80/92 (86.96%) RBPJ;RUNX3;HLA-DOB;...
Leishmaniasis -1.85 1.79e-2 67/77 (87.01%) IFNG;NFKBIA;TLR2;...
Staphylococcus aureus infection -1.87 1.46e-2 72/95 (75.79%) FPR3;FGG;C3;...
Influenza A -1.87 1.49e-2 156/172 (90.7%) IKBKG;CIITA;AKT2;...
C-type lectin receptor signaling pathway -1.88 1.53e-2 93/104 (89.42%) MDM2;PIK3CB;MAPK14;...
Allograft rejection -1.91 9.92e-3 32/38 (84.21%) IFNG;GZMB;TNF;...
Toxoplasmosis -1.94 2.38e-3 103/112 (91.96%) HLA-DOB;LAMC1;AKT1;...
Intestinal immune network for IgA production -1.95 2.98e-3 38/48 (79.17%) LTBR;HLA-DOA;HLA-DRA;...
Systemic lupus erythematosus -2.03 3.97e-3 45/135 (33.33%) GRIN2A;SNRPD3;TRIM21;...
Inflammatory bowel disease -2.09 0.00e+0 58/65 (89.23%) TLR5;NFATC1;IFNG;...
Asthma -2.11 0.00e+0 25/31 (80.65%) HLA-DRB1;IL3;CCL11;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.03uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H